Home Congenital adrenal hyperplasia in children – a survey on the current practice in the UK
Article
Licensed
Unlicensed Requires Authentication

Congenital adrenal hyperplasia in children – a survey on the current practice in the UK

  • Usha Niranjan EMAIL logo and Anuja Natarajan
Published/Copyright: March 7, 2015

Abstract

Background: Congenital adrenal hyperplasia (CAH) in children varies in presentation and progression with several challenges in optimal management. Effective treatment is to achieve normal growth and development while avoiding adrenal crisis and hyperandrogenisation.

Aim: Our aim was to ascertain the current practice in the UK on CAH management in children in comparison with the recommendations made by the Endocrine Society.

Methods: An online survey was emailed to the British Society of Paediatric Endocrinology (BSPED) members requesting a response from each centre regarding CAH management.

Results: The survey was completed by 35 out of 92 centres (38% response rate). Tertiary centres constituted 22/35, while 8/35 were district general hospitals providing tertiary services. Treatment varied among centres with 25/35 using 10–15 mg/m2/day of hydrocortisone and 21/35 of centres using 50–150 μg/day of fludrocortisone. The frequency of clinical reviews was contentious and varied depending on the child’s age and clinical status. Reviews were done 3–4 monthly in 68% and 6 monthly in 31% of centres. The frequency of investigations including 17-hydroxyprogesterone (66% 3–6 monthly; 34% yearly), testosterone/dehydroepiandrosterone sulphate (37% 6 monthly; 51% yearly), renin/aldosterone (31% 6 monthly; 69% yearly) and bone age (83% yearly, 6% 2 yearly) varied significantly among centres. Genetic counselling was provided at diagnosis in 69% of the centres while surgical (66%) and psychology (80%) input were provided on an as required basis.

Conclusion: Our survey highlights the diversity in managing children with CAH in the UK as compared with the recommendations of the Endocrine Society. It also demonstrates inconsistent involvement of essential specialist services, which are essential for optimal management of this condition.


Corresponding author: Usha Niranjan, MRCPCH, Sheffield Children’s Hospital, Western Bank, Sheffield S10 2TH, UK, Phone: +0044-798-6841120, Fax: +0044-114-2267956, E-mail:

Acknowledgments

The authors would like to acknowledge the British Society of Paediatric Endocrinology and Diabetes Audit department for reviewing the survey questionnaire and for help with the dissemination of the survey to its members.

References

1. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol 2010; 95:4133–60.10.1210/jc.2009-2631Search in Google Scholar PubMed PubMed Central

2. Trapp CM, Speiser PW, Oberfield SE. Congenital adrenal hyperplasia: an update in children. Curr Opin Endocrinol Diabetes Obes 2011;18:166–70. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3638875&tool=pmcentrez&rendertype=abstract.10.1097/MED.0b013e328346938cSearch in Google Scholar PubMed PubMed Central

3. Trapp CM, Oberfield SE. Recommendations for treatment of nonclassic congenital adrenal hyperplasia (NCCAH): an update. Steroids 2012;77:342–6. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3638754&tool=pmcentrez&rendertype=abstract.10.1016/j.steroids.2011.12.009Search in Google Scholar PubMed PubMed Central

4. Bonfig W, Bechtold S, Schmidt H, Knorr D, Schwarz HP. Reduced final height outcome in congenital adrenal hyperplasia under prednisone treatment: deceleration of growth velocity during puberty. J Clin Endocrinol Metab 2007;92:1635–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17299071.10.1210/jc.2006-2109Search in Google Scholar PubMed

5. Balsamo A, Cicognani A, Baldazzi L, Barbaro M, Baronio F, et al. CYP21 genotype, adult height, and pubertal development in 55 patients treated for 21-hydroxylase deficiency. J Clin Endocrinol Metab 2003;88:5680–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14671153.10.1210/jc.2003-030123Search in Google Scholar PubMed

6. Bonfig W, Pozza SB, Schmidt H, Pagel P, Knorr D, et al. Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation. J Clin Endocrinol Metab 2009;94:3882–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19622620.10.1210/jc.2009-0942Search in Google Scholar PubMed

7. Merke DP, Cho D, Calis KA, Keil MF, Chrousos GP. Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2001;86:441–5.10.1210/jcem.86.1.7275Search in Google Scholar PubMed

8. German A, Suraiya S, Tenenbaum-Rakover Y, Koren I, Pillar G, et al. Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab 2008;93:4707–10. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18782876.10.1210/jc.2008-0519Search in Google Scholar PubMed

9. Hindmarsh PC. Management of the child with congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:193–208. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19500763.10.1016/j.beem.2008.10.010Search in Google Scholar PubMed

10. Charmandari E, Brook CG, Hindmarsh PC. Why is management of patients with classical congenital adrenal hyperplasia more difficult at puberty? Arch Dis Child 2002;86:266–9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1719167&tool=pmcentrez&rendertype=abstract.10.1136/adc.86.4.266Search in Google Scholar PubMed PubMed Central

11. Kim MS, Ryabets-Lienhard A, Geffner ME. Management of congenital adrenal hyperplasia in childhood. Curr Opin Endocrinol Diabetes Obes 2012;19:483–8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3584711&tool=pmcentrez&rendertype=abstract.10.1097/MED.0b013e32835a1a1bSearch in Google Scholar PubMed PubMed Central

12. Meyer-Bahlburg H. Health-related quality of life in intersexuality. Acta Paediatr 1999;88:114–5. Available at: http://doi.wiley.com/10.1111/j.1651-2227.1999.tb14367.x.10.1111/j.1651-2227.1999.tb14367.xSearch in Google Scholar PubMed


Supplemental Material

The online version of this article (DOI: 10.1515/jpem-2014-0362) offers supplementary material, available to authorized users.


Received: 2014-9-8
Accepted: 2015-1-23
Published Online: 2015-3-7
Published in Print: 2015-7-1

©2015 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Highlight: Thyroid
  3. Thyroid disorders revisited
  4. Genetic analysis of the paired box transcription factor (PAX8) gene in a cohort of Polish patients with primary congenital hypothyroidism and dysgenetic thyroid glands
  5. Prognostic factors in pediatric differentiated thyroid cancer patients with pulmonary metastases
  6. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients
  7. Evaluation of inflammatory and oxidative biomarkers in children with well-controlled congenital hypothyroidism
  8. Investigation of autoimmune diseases accompanying Hashimoto’s thyroiditis in children and adolescents and evaluation of cardiac signs
  9. Neonatal thyroid storm accompanied with severe anaemia
  10. Functional characterization of the novel sequence variant p.S304R in the hinge region of TSHR in a congenital hypothyroidism patients and analogy with other formerly known mutations of this gene portion
  11. Subclinical hypothyroidism as a rare cofactor in chronic kidney disease (CKD) – related anemia
  12. Cytometric analysis of perforin expression in NK cells, CD8+, and CD4+ lymphocytes in children with autoimmune Hashimoto’s thyroiditis – a preliminary study
  13. Papillary thyroid cancer and autoimmune polyglandular syndrome
  14. Review article
  15. Should radioiodine be the first-line treatment for paediatric Graves’ disease?
  16. Image in pediatric endrocrinology
  17. Diffusion-weighted magnetic resonance imaging in a case of severe classic maple syrup urine disease
  18. Original articles
  19. Novel mutations of DAX1 (NR0B1) in two Chinese families with X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism
  20. Rickets and vitamin D deficiency in Alaska native children
  21. Persistent elevation of fibroblast growth factor 23 concentrations in healthy appropriate-for-gestational-age preterm infants
  22. Parents’ experiences of having a baby with ambiguous genitalia
  23. Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty
  24. Congenital adrenal hyperplasia in children – a survey on the current practice in the UK
  25. Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome
  26. Influence of the body weight on the onset and progression of puberty in boys
  27. Therapy monitoring in congenital adrenal hyperplasia by dried blood samples
  28. Hyperinsulinemic hypoglycemia: think of hyperinsulinism/hyperammonemia (HI/HA) syndrome caused by mutations in the GLUD1 gene
  29. Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds
  30. Monitoring gonadotropin-releasing hormone analogue (GnRHa) treatment in girls with central precocious puberty: a comparison of four methods
  31. Dietary intake, body composition, and physical activity among young patients with type 1 diabetes mellitus
  32. Metabolic syndrome in obese children and adolescents in Serbia: prevalence and risk factors
  33. Progressive osseous heteroplasia, as an isolated entity or overlapping with Albright hereditary osteodystrophy
  34. Patient reports
  35. 17α-Hydroylase/17,20-lyase deficiency related to P.Y27*(c.81C>A) mutation in CYP17A1 gene
  36. A patient developing anaphylaxis and sensitivity to two different GnRH analogues and a review of literature
  37. Idiopathic short stature due to novel heterozygous mutation of the aggrecan gene
  38. Triple A syndrome with a novel indel mutation in the AAAS gene and delayed puberty
  39. Case report: long-term follow-up of a 45,X male with SHOX haploinsufficiency
  40. Antenatal Bartter syndrome presenting as hyperparathyroidism with hypercalcemia and hypercalciuria: a case report and review
  41. Successful use of continuous subcutaneous hydrocortisone infusion after bilateral adrenalectomy secondary to bilateral pheochromocytoma
  42. Donohue syndrome: a new case with a new complication
  43. Euprolactinemic galactorrhea secondary to domperidone treatment
  44. 17βHSD-3 enzyme deficiency due to novel mutations in the HSD17B3 gene diagnosed in a neonate
  45. Two different patterns of mini-puberty in two 46,XY newborns with 17β-hydroxysteroid dehydrogenase type 3 deficiency
  46. Short communication
  47. Early onset hearing loss in autosomal recessive hypophosphatemic rickets caused by loss of function mutation in ENPP1
Downloaded on 30.11.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2014-0362/html?lang=en
Scroll to top button